These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 32227030)

  • 1. Advances in covalent kinase inhibitors.
    Abdeldayem A; Raouf YS; Constantinescu SN; Moriggl R; Gunning PT
    Chem Soc Rev; 2020 May; 49(9):2617-2687. PubMed ID: 32227030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Exploration of Privileged Warheads for Covalent Kinase Drug Discovery.
    Zhao Z; Bourne PE
    Pharmaceuticals (Basel); 2022 Oct; 15(11):. PubMed ID: 36355497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.
    Lu X; Smaill JB; Patterson AV; Ding K
    J Med Chem; 2022 Jan; 65(1):58-83. PubMed ID: 34962782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA-approved small-molecule kinase inhibitors.
    Wu P; Nielsen TE; Clausen MH
    Trends Pharmacol Sci; 2015 Jul; 36(7):422-39. PubMed ID: 25975227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug discovery considerations in the development of covalent inhibitors.
    Mah R; Thomas JR; Shafer CM
    Bioorg Med Chem Lett; 2014 Jan; 24(1):33-9. PubMed ID: 24314671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted covalent drugs of the kinase family.
    Singh J; Petter RC; Kluge AF
    Curr Opin Chem Biol; 2010 Aug; 14(4):475-80. PubMed ID: 20609616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reaction profiling of a set of acrylamide-based human tissue transglutaminase inhibitors.
    Jasim MH; Rathbone DL
    J Mol Graph Model; 2018 Jan; 79():157-165. PubMed ID: 29179065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics.
    Yu HS; Gao C; Lupyan D; Wu Y; Kimura T; Wu C; Jacobson L; Harder E; Abel R; Wang L
    J Chem Inf Model; 2019 Sep; 59(9):3955-3967. PubMed ID: 31425654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opportunities and challenges for the development of covalent chemical immunomodulators.
    Backus KM; Cao J; Maddox SM
    Bioorg Med Chem; 2019 Aug; 27(15):3421-3439. PubMed ID: 31204229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug discovery for a new generation of covalent drugs.
    Kalgutkar AS; Dalvie DK
    Expert Opin Drug Discov; 2012 Jul; 7(7):561-81. PubMed ID: 22607458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design.
    Ray S; Murkin AS
    Biochemistry; 2019 Dec; 58(52):5234-5244. PubMed ID: 30990686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparameter Kinetic Analysis for Covalent Fragment Optimization by Using Quantitative Irreversible Tethering (qIT).
    Craven GB; Affron DP; Kösel T; Wong TLM; Jukes ZH; Liu CT; Morgan RML; Armstrong A; Mann DJ
    Chembiochem; 2020 Dec; 21(23):3417-3422. PubMed ID: 32659037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covalent inhibitors: an opportunity for rational target selectivity.
    Lagoutte R; Patouret R; Winssinger N
    Curr Opin Chem Biol; 2017 Aug; 39():54-63. PubMed ID: 28609675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Highly Selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors by a Covalent Fragment-Based Approach.
    Huang F; Hu H; Wang K; Peng C; Xu W; Zhang Y; Gao J; Liu Y; Zhou H; Huang R; Li M; Shen J; Xu Y
    J Med Chem; 2020 Jul; 63(13):7052-7065. PubMed ID: 32459096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CovalentInDB: a comprehensive database facilitating the discovery of covalent inhibitors.
    Du H; Gao J; Weng G; Ding J; Chai X; Pang J; Kang Y; Li D; Cao D; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1122-D1129. PubMed ID: 33068433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irreversible protein kinase inhibitors.
    Garuti L; Roberti M; Bottegoni G
    Curr Med Chem; 2011; 18(20):2981-94. PubMed ID: 21651479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research progress of the small molecule covalent inhibitors].
    Yang B; Wang WJ; Li LL
    Yao Xue Xue Bao; 2014 Feb; 49(2):158-65. PubMed ID: 24761604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in Covalent Drug Discovery.
    Schaefer D; Cheng X
    Pharmaceuticals (Basel); 2023 Apr; 16(5):. PubMed ID: 37242447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covalent drugs targeting histidine - an unexploited opportunity?
    Che J; Jones LH
    RSC Med Chem; 2022 Oct; 13(10):1121-1126. PubMed ID: 36325394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inspired by Nature: The 3-Halo-4,5-dihydroisoxazole Moiety as a Novel Molecular Warhead for the Design of Covalent Inhibitors.
    Pinto A; Tamborini L; Cullia G; Conti P; De Micheli C
    ChemMedChem; 2016 Jan; 11(1):10-4. PubMed ID: 26607551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.